Isquemia crónica de miembros inferiores. Enfermedad arterial periférica

  1. Ducajú, G. Moñux
  2. Conejero, A. Martín
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2017

Issue Title: Enfermedades cardiológicas (VII) Enfermedades vasculares

Series: 12

Issue: 41

Pages: 2440-2447

Type: Article

DOI: 10.1016/J.MED.2017.09.012 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Abstract Peripheral arterial disease (PAD) is one of the most prevalent conditions and coexistence with vascular disease in other territories is common. Atherosclerosis is the most common cause of PAD and is associated with cardiovascular risk factors. PAD is caused by progressive obstruction of the arteries in the legs. The clinic varies according to the magnitude of the deficit. Patients may remain asymptomatic in early stages, present intermittent claudication, which is the most frequent symptom, or present pain at rest or trophic lesions in advanced stages. To quantify the severity the best test is the ankle / arm index. It presents prognostic value for the limb and for the development of cardiovascular events, mainly acute myocardial infarction (AMI). Varies depending on the clinic and the affected territory. The medical treatment consists of the control of risk factors and cilostazol as treatment of claudication. Conventional and endovascular surgical revascularization techniques are indicated when there is crippling claudication or more severe ischemia in the form of pain at rest or trophic lesions.

Bibliographic References

  • Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510-51.
  • Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472-9.
  • Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the Nacional Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110:738-43.
  • Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
  • Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer HR, Garside DB. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-7.
  • Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. Inter Society Consensus for the Management of Peripheral Arte-rial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S1-S75.
  • Hirsch AT, Treat-Jacobson D, Lando HA, Neaton JD, Dyer AR, Garside DB. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med. 1997; 2:243-51.
  • Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand. 1987;221:253-60.
  • Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69 Suppl:S24-6.
  • Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL. J Am Coll Cardiol. 2006;47: 1239-312.
  • Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421-31.
  • Nayor M, Vasan RS. Recent update to the us cholesterol treatment guidelines: a comparison with international guidelines. Circulation. 2016; 133(18):1795-806.
  • Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med. 1992;231:273-9.
  • Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126:2890-909.
  • Lin JS, Olson CM, Johnson ES, Whitlock EP. The anklebrachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:333-41.
  • Michael S. Conte, MD, (Co-Chair),a Frank B. Pomposelli, MD, (Co-Chair),b Daniel G. Clair, MD,c Patrick J. Geraghty, MD,d, James F. McKinsey, MD,e Joseph L. Mills, MD,f Gregory L. Moneta, MD,g M. Hassan Murad, MD,h Richard J. Powell, MD,i Amy B. Reed, MD,j Andres Schanzer, MD,k and Anton N. Sidawy, MD, MPH. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg. 2015; 61:2S-41S.
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25)Suppl2:S1-45.
  • Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
  • Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481-6.
  • Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359-64
  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
  • CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-39.
  • Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2008;(4):CD000990.
  • Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S1-S75.
  • Brewster DC. Clinical and anatomical considerations for surgery in aortoiliac disease and results of surgical treatment. Circulation. 1991;83(2)Suppl:I42-52.
  • Antonopoulos CN, Mylonas SN, Moulakakis KG, Sergentanis TN, Sfyroeras GS, Lazaris AM. A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg. 2017;65(1):234-45.
  • Serrano FJ, Martín A. Enfermedad arterial periférica: aspectos fisiopatológicos, clínicos y terapéuticos. Rev Esp Cardiol. 2007;60(9):969-82.
  • Conte MS. Bypass versus angioplasty in severe ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. J Vasc Surg. 2010;51(5) Suppl:69S-75S.
Data source: Dialnet